Drug Profile
Carbon-11-TASP 0410699
Alternative Names: [11C]TASP-0410699; Carbon-11-TASP-0410699; TASP0410699Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Taisho Pharmaceutical
- Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in CNS-disorders(Diagnosis) in USA (IV)
- 13 May 2015 Taisho Pharmaceutical plans a phase I trial in Healthy volunteers in USA (NCT02448212)
- 01 May 2015 Phase-I clinical trials in CNS disorders (Diagnosis) in USA (IV) (NCT02448212)